L'intégrine α IIbβ 3 : De la biologie cellulaire aux médicaments antithrombotiques

Hematologie

Volumn 3, Issue 5, 1997, Pages 407-415

  Nurden, Alan T ^a   Ruan, Jian ^a   Nurden, Paquita ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antithrombotic strategies.the integrin iib 3 : From cellular biology to anti tfiromboric drugs; Glanzmann's thrombasthenia; Gp llb llla complexes; Platelets

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; INTEGRIN; LAMIFIBAN; VON WILLEBRAND FACTOR;

CONFORMATIONAL TRANSITION; CROSS LINKING; CYTOLOGY; GLANZMANN DISEASE; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LIGAND BINDING; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 0031458486     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Andrews RK, Lopez JA, Berndt MC, Molecular mechanisms of platelet adhesion and activation. IntJ Biochem Cell Biol 1997 ; 29 : 91-105.
2. Roth GJ, Developing relationships : arterial platelet adhesion, glycoprotein Ib, and leucinerich glycoproteins. Blood 1991 ; 77 : 5-19.
3. Nurden AT, Nurden P, A review of the role of platelet membrane glycoproteins in the plateletvessel wall interaction. Ballières Clin Haematol 1993; 6: 653-90.
4. Morion LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ, Integrin a;,-independent activation of platelets by simple collagenlike peptides : collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for a:|-independent platelet reactivity. Biochem J 1995 ; 306 : 337-44.
5. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR, Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997 ; 386 : 502-6.
6. Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Cachet C, The P2Y, receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Letts 1997 ; 403 : 26-30.
7. Levy-Toledano S, Gallet C, Nadal F, Bryckaert M, MacloufJ, RosaJP, Phosphorylation and dephosphorylalion mechanisms in platelet function : a tightly regulated balance. Thromb Haemosl 1997; 78: 226-33.
8. Nurden P, Humbert M, Piotrowicz RS, Bihour C, Poujol C, Nurden AT, Kunicki TJ, The distribution of ligand-occupied a.:t3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site (LIBS) recognized by monoclonal antibody AP-6. Blood 1996 ; 88 : 887-99.
9. Youssefian T, Massé JM, Rendu F, Guichardj, Cramer EM, Platelet and megakaryocyte dense granules contain glycoproteins Ib and llb-llla. Blood 1997 ; 89 : 4047-57.
10. Kieffer N, Phillips DR, Platelet membrane glycoproteins : functions in cellular interactions. Ann Rev Cell Bid 1990 ; 6 : 329-57.
11. l. Nurden P, Poujol C, Nurden AT, The evolution of megakaryocytes to platelets. Baillieres Clin Haematol 1997; 10: 1-27.
12. Poujol C, Nurden AT, Nurden P, Ultrastructural analysis of the distribution of the vitronectin receptor (c^j) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the a-granule membrane. Br J Haematol 1997; 97: 823-35.
13. 3 for angiogenesis. Science 1994 ; 264 : 569-71.
14. 3 and platelet function. Thromb Haemost 1997 ; 78 : 96-100.
15. Farrell DH, Thiagarajan P, Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994; 269: 226-31.
16. Legrand C, Dubernard V, Rabhi-Sabile S, Morandi da Silva V, Functional and clinical significance of thrombospondin. Platelets 1997; 8: 211-23.
17. 3 (platelet GP llb-llla) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest 1991 ; 88 : 1 128-34.
18. French D, Coller BS, Hematolog'cally important mutations : Glanzmann thrombasthenia. Blood Cells, Molecules and Diseases 1996 ; 23: 39-51.
19. George JN, Caen JP, Nurden AT, Glanzmann's thrombasthenia : the spectrum of clinical disease and molecular abnormalities in 64 patients. Blood 1990; 75 : 1383-95.
20. 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 1990; 249: 915-8.
21. Nurden AT, Polymorphisms of human platelet membrane glycoproteins : structure and clinical significance. Thromb Haemost 1995 ; 74 : 345-51.
22. Tozer EC, Liddington RC, Sulcliffe MJ, Smeeton AH, Loftus JC, Ligand binding to integrin alphallbbetaS is dependent on a MIDAS-like domain in the beta3 subunit. J Biol Chem 1996 ; 271 : 21978-84.
23. IIb (GP lib). Thromb Haemost 1995; 73 : 11 89 (abstr).
24. 3 (glycoprotein llb-llla] in a variant of Glanzmann thrombasthenia. Pioc Noll Acad Sei USA 1992; 89: 10169-73.
25. Weiss ET, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, WeissJL, Gerstenblith G, Goldschmidt-Clermont Pj. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New EnglJMed 1996 ; 334 : 1090-4.
26. A1/A2 polymorphism of platelet glycoprotein Ilia and risks of myocardial infarction, stroke, and venous thrombosis, foncef 1997 ; 349 : 385-8.
27. 3 subunit. Biochem J 1996; 314 : 769-79.
28. Hughes PE, Diaz-Gonzalez F, Leong L, Wu C, McDonald JA, Shattil SJ, Ginsberg MH, Breaking the integrin hinge. A defined structural constraint regulates integrin signalling. J Biol Chern 1996; 271 : 6571-4.
29. 3. Thromb Haemost 1997 ; 78 : 220-5.
30. Guinebault C, Payrastre B, Racoud-Sultan C, Mazarguil H, Breton M, Mauco G, Plantavid M, Chap H, Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Bio H 995 ; 129: 831-42.
31. 3 EMBOJ 1996 ; 15 : 5760-71.
32. Abrams SC, Shattil SJ, Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991 ; 65 : 467-73.
33. Michelson AD, Flow cytometry : a clinical test of platelet function. Blood 1996; 87: 4925-36.
34. Harrison P, Wilbourn B, Debeli N, Vainchenker W, Breton-GoriusJ, LawrieAS, Masse JM, Savidge GF, Cramer EM, Uptake of plasma fibrinogen into the a-granules of human megakaryocytes and platelets. J Clin Invest 1989 ; 84: 1320-4.
35. Wencel-Drake JD, Frelinger AL III, Dieter MG, Lam SCT, Arg-Gly-Asp-dependeni occupancy of GP llb/llla by applagin : evidence for internalization and cycling of a platelet integrin. Blood 1993; 81 :62-9.
36. Humbert M, Nurden P, Bihour C, PasquetJM, WincklerJ, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurden AT, Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vase Biol 1996; 16: 1532-43.
37. 3 and its ligand and induces selective movements of ligand-occupied integrin. j Biol Chem 1996 ; 271 : 7004-11.
38. Nurden P, Heilmann E, Paponneau A, Nurden A, Two-way trafficking of membrane glycoproleins on thrombin-activated human platelets. Sem Hematol 1994 ; 31 : 240-50.
39. Schrör K, Antiplatelet drugs. A comparative review. Drugs 1995 ; 50 : 7-28.
40. Gachet C, Hechler B, Léon C, Vial C, Ohlmann P, Cazenave JP, Purinergic receptors on blood platelets. Platelets 1996 ; 7 : 261-8.
41. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden AT, An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets J Clin Invest 1995 ; 95 : 1612-22.
42. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
43. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamilzky M, Walter H, Zitzmann-Roth EM, Richard! G, All E, Schmitt C, Ulm K, A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl J A/led 1996; 334: 1084-9.
44. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ, Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. Circulation 1992; 86: 1364-8.
45. Coller BS, Blockode of platelet GPIIb/llla receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-80.
46. Gold HK, Gimple LW, YasudaT, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS, Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein llb/llla in patients with unstable angina pectoris. J Clin Invest 1990 ; 86 : 651-9.
47. Eccleston D, Topol EJ, Inhibitors of platelet glycoprotein llb/llla as augmenters of thrombolysis. Coronary Artery Disease 1995 ; 6 : 947-55.
48. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein llb/llla receptor in high-risk coronary angioplasty. New Eng/ J Med 1994 ; 330 : 95661.
49. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, WorleyS, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, LeeKL, WillersonJT on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet llb/llla integrin for reduction of clinical restenosis : results at six months. Lancet 1994 ; 343 : 881-6.
50. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, WillersonJT, Chandra NC, Guerci AD, FergusonJJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, BahrRD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, GottdienerP, du Mee C, Kilt MM, Gerstenblith G, Effects of integrilin, a platelet glycoprotein llb/llla receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996; 94 : 2083-9.
51. Lefkovits J, Plow EF, Topol EJ, Platelet glycoprotein llb/llla receptors in cardiovascular medicine. New Engl J Med 1995; 332: 1553-9.
52. Théroux P, Kouz S, Roy L, Knudtson ML, DiodatiJG, Marquis JF, NasmithJ, Fung AY, BoudreaultJR, Delage F, Dupuis R, Keils C, Bqkslag M, Steiner B, Rapold HJ, on behalf of the investigators. Platelet membrane receptor glycoprotein llb/llla antagonism in unstable angina. The Canadian Lamifiban study. Circulation 1996 ; 94 : 899-905.
53. Mousa SA, De Grado WF, Mu DX, Kapil RP, lucchesi BR, Reilly TM, Oral anliplalelel, antithrombotic efficacily of DMP 728, a novel platelet GP llb-llla antagonist. Circulation 1996 ; 93 : 537-43.
54. Nicolson N, Panzer-Knodle S, Salyers A, Taite BB, Szalony JA, Haas NF, King LW, ZablockiJA, Keller BT, Broschat K, SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995 ; 91 : 403-10.
55. Ohmann EM, Kleiman NS, Gacioch G, Worley SJ, Navetta Fl, Talley D, Anderson V, Ellis SG, Cohen M, Sproggs D, Miller M, Keraiakes D, Yakubov S, Kitt MM, Sig'mon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein llb/llla integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. Circulation 1997 ; 95 : 846-54.
56. Kleimann NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF, Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab : implications for inhibition of the internal pool of GP llb-llla receptors. J Am Coll Cordial 1995 ; 26 : 1665-71.
57. Bihour C, Durrieujais C, Macchi I, Coste P, Besse P, Nurden P, Nurden AT, Expression of activation markers on platelets of patients receiving abciximab (c7E3 Fab, Reo Pro) and undergoing percutaneous transluminal coronary angioplasty for refractory unstable angina. Ms soumis.